Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dichlorphenamide

FDA-approved product (tablet, oral), marketed as Daranide, Dichlorphenamide, Keveyis and 1 more.

Registered studies
2
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dichlorphenamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Carbonic anhydrase inhibitors
FDA pharmacologic class
Carbonic Anhydrase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis73.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Dichlorphenamide in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dichlorphenamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hyper- and Hypokalemic Periodic Paralysis Study

    NCT00494507 · start 2007-06

    Registered record
    Registry ID
    NCT00494507
    Conditions
    Hyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis
    Interventions
    Dichlorphenamide (double-blind); Placebo (double-blind); Dichlorphenamide (open-label)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2013-05
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis
    InterventionDichlorphenamide (double-blind); Placebo (double-blind); Dichlorphenamide (open-label)
    PhasePhase 3
    Registry statusCompleted

  • Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders

    NCT00004802 · start 1992-06

    Registered record
    Registry ID
    NCT00004802
    Conditions
    Paralysis, Hyperkalemic Periodic; Hypokalemic Periodic Paralysis; Paramyotonia Congenita
    Interventions
    dichlorphenamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1992-06
    Completion
    Not recorded
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParalysis, Hyperkalemic Periodic; Hypokalemic Periodic Paralysis; Paramyotonia Congenita
    Interventiondichlorphenamide
    PhasePhase 3
    Registry statusCompleted